Chase Malackowski was diagnosed with Ewing's Sarcoma at eight years old. After trialing a "single patient Investigational New Drug" (IND) which allowed him access to BPM31510, Chase has been ...
(NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from its ongoing ...